47 ProductsIn development (3)
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.
Evidence-based recommendations on a range of health and care topics. Find out more about NICE guidelines
Statements covering priority areas for quality improvement (including ways to measure quality). Find out more about Quality standards.
Highly specialised technologies guidance
Recommendations on the use of highly specialised medicines and treatments for very rare conditions. Find out more about Highly specialised technologies guidance.
Interventional procedures guidance
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS. Find out more about Interventional procedures guidance.
Summaries of the best available evidence for selected new medicines, off-label use of licensed medicines and unlicensed medicines. Find out more about Evidence summaries.
New guidance and advice
Guidance and advice added since November 2017
Comment on guidance in development
Current guidance in consultation
Latest news on this topic
NICE has published draft guidance in which dinutuximab beta is not recommended as a treatment for high-risk neuroblastoma – a rare type of cancer that mainly affects children and young people.